{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:22:11Z","timestamp":1790900531252,"version":"4.1.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"9","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Anti-CD19 chimeric antigen receptor (CAR)\u2013engineered T and natural killer (NK) cell therapies have revolutionized the treatment of B-cell malignancies, but challenges including CD19 antigen loss greatly hinder their full therapeutic potential. Here, we revealed that cotreatment with anti-CD19 monoclonal antibody enhances antitumor activity of anti-CD19 CAR-T and -NK cells. Even though the treated antibody interferes with CD19 antigen binding of CAR, it significantly induces rapid detachment of anti-CD19 CAR effector cells from target cells, facilitating improved serial killing. This reduced interaction between CAR effector cells and target cells also leads to the alleviation of CAR-mediated trogocytosis. Interestingly, cotreatment with anti-CD19 antibody reveals time-dependent effects on the antitumor activity of anti-CD19 CAR-T cells, characterized by a reduction in early T cell activation followed by sustained high activity during prolonged exposure to target cells. This temporal modulation ultimately results in enhanced antitumor potency in\u00a0vivo. These findings underscore the improved therapeutic efficacy achieved by combining anti-CD19 antibody with anti-CD19 CAR-T or -NK cells against B-cell malignancies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024025673","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T20:23:37Z","timestamp":1733775817000},"page":"956-969","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T\/-NK cells and reduces trogocytosis"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7493-8363","authenticated-orcid":false,"given":"Seung Kwon","family":"Koh","sequence":"first","affiliation":[{"name":"1Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-3064","authenticated-orcid":false,"given":"Hyojin","family":"Kim","sequence":"additional","affiliation":[{"name":"2Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohwa","family":"Han","sequence":"additional","affiliation":[{"name":"3Department of Materials Science and Engineering, Seoul National University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2061-2755","authenticated-orcid":false,"given":"Hantae","family":"Jo","sequence":"additional","affiliation":[{"name":"4Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsang","family":"Doh","sequence":"additional","affiliation":[{"name":"3Department of Materials Science and Engineering, Seoul National University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeehun","family":"Park","sequence":"additional","affiliation":[{"name":"5Department of Molecular Bioscience, College of Biomedical Science, Kangwon National University, Chuncheon-si, Republic of Korea"},{"name":"6Multidimensional Genomics Research Center, Kangwon National University, Chuncheon-si, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8601-8283","authenticated-orcid":false,"given":"Minh Ha","family":"Nguyen","sequence":"additional","affiliation":[{"name":"2Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Young","family":"Kim","sequence":"additional","affiliation":[{"name":"4Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haneul","family":"Kim","sequence":"additional","affiliation":[{"name":"1Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hwan","family":"Lee","sequence":"additional","affiliation":[{"name":"7Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9649-1892","authenticated-orcid":false,"given":"Chan Hyuk","family":"Kim","sequence":"additional","affiliation":[{"name":"8Innovative Pharmaceutical Sciences Program, School of Transdisciplinary Innovations, Seoul National University, Seoul, Republic of Korea"},{"name":"9Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, Republic of Korea"},{"name":"10Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6861-3282","authenticated-orcid":false,"given":"Duck","family":"Cho","sequence":"additional","affiliation":[{"name":"1Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea"},{"name":"4Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"},{"name":"11Cell and Gene Therapy Institute, Samsung Medical Center, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2025032119425076100_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-immunol-042718-041407","article-title":"Emerging cellular therapies for cancer","volume":"37","author":"Guedan","year":"2019","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"2025032119425076100_bib2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2025032119425076100_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2025032119425076100_bib4","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19\u2013specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"2025032119425076100_bib5","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res"},{"issue":"1","key":"2025032119425076100_bib6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J\u00a0Exp Clin Cancer Res"},{"issue":"3","key":"2025032119425076100_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"2025032119425076100_bib8","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","article-title":"Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes","volume":"3","author":"Korell","year":"2022","journal-title":"Med"},{"issue":"4","key":"2025032119425076100_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"23-24","key":"2025032119425076100_bib10","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s00508-021-01948-2","article-title":"CAR T-cell therapy and critical care : a survival guide for medical emergency teams","volume":"133","author":"Messmer","year":"2021","journal-title":"Wien Klin Wochenschr"},{"issue":"12","key":"2025032119425076100_bib11","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"7","key":"2025032119425076100_bib12","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/s41375-022-01585-2","article-title":"Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion","volume":"36","author":"Olson","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"2025032119425076100_bib13","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"issue":"9","key":"2025032119425076100_bib14","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41590-023-01571-5","article-title":"CTLA-4 tail fusion enhances CAR-T antitumor immunity","volume":"24","author":"Zhou","year":"2023","journal-title":"Nat Immunol"},{"issue":"10","key":"2025032119425076100_bib15","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","article-title":"KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape","volume":"28","author":"Li","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"2025032119425076100_bib16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood.2022018905","article-title":"CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS","volume":"143","author":"Sakemura","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2025032119425076100_bib17","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"2025032119425076100_bib18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/14712598.2021.1884677","article-title":"Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma","volume":"21","author":"Salles","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"2025032119425076100_bib19","doi-asserted-by":"crossref","first-page":"1274556","DOI":"10.3389\/fimmu.2023.1274556","article-title":"Preclinical study of CD19 detection methods post tafasitamab treatment","volume":"14","author":"Ilieva","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"2025032119425076100_bib20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/cyto.a.24690","article-title":"Accurate identification of cell doublet profiles: comparison of light scattering with fluorescence measurement techniques","volume":"103","author":"Rico","year":"2023","journal-title":"Cytometry A"},{"key":"2025032119425076100_bib21","doi-asserted-by":"crossref","first-page":"864868","DOI":"10.3389\/fimmu.2022.864868","article-title":"Programmable attenuation of antigenic sensitivity for a nanobody-based EGFR chimeric antigen receptor through hinge domain truncation","volume":"13","author":"McComb","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"2025032119425076100_bib22","first-page":"293","article-title":"Activation of human B cells through the CD19 surface antigen results in homotypic adhesion by LFA-1-dependent and -independent mechanisms","volume":"73","author":"Smith","year":"1991","journal-title":"Immunology"},{"issue":"8","key":"2025032119425076100_bib23","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering natural killer cells for cancer immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol Ther"},{"issue":"4","key":"2025032119425076100_bib24","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"issue":"4","key":"2025032119425076100_bib25","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2025032119425076100_bib26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2025032119425076100_bib27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12943-023-01886-9","article-title":"Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol Cancer"},{"issue":"7750","key":"2025032119425076100_bib28","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR\u00a0T\u00a0cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"2025032119425076100_bib29","doi-asserted-by":"crossref","first-page":"1165870","DOI":"10.3389\/fimmu.2023.1165870","article-title":"Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL","volume":"14","author":"Aparicio-Perez","year":"2023","journal-title":"Front Immunol"},{"issue":"23","key":"2025032119425076100_bib30","doi-asserted-by":"crossref","first-page":"9421","DOI":"10.1073\/pnas.1300140110","article-title":"Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand","volume":"110","author":"Nakamura","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2025032119425076100_bib31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12943-023-01894-9","article-title":"Outsmarting trogocytosis to boost CAR\u00a0NK\/T cell therapy","volume":"22","author":"Ramezani","year":"2023","journal-title":"Mol Cancer"},{"issue":"8","key":"2025032119425076100_bib32","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"2025032119425076100_bib33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.molimm.2020.08.015","article-title":"Cross-reactivity of mouse IgG subclasses to human Fc gamma receptors: antibody deglycosylation only eliminates IgG2b binding","volume":"127","author":"Temming","year":"2020","journal-title":"Mol Immunol"},{"key":"2025032119425076100_bib34","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.phrs.2017.11.035","article-title":"CAR-T cells and combination therapies: What's next in the immunotherapy revolution?","volume":"129","author":"Ramello","year":"2018","journal-title":"Pharmacol Res"},{"issue":"6","key":"2025032119425076100_bib35","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3390\/cancers14061403","article-title":"Emerging novel combined CAR-T cell therapies","volume":"14","author":"Nguyen","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/9\/956\/2357282\/blood_bld-2024-025673-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/9\/956\/2357282\/blood_bld-2024-025673-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T20:48:32Z","timestamp":1742590112000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/9\/956\/534403\/Anti-CD19-antibody-cotreatment-enhances-serial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,2,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025673","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}